Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer

Hye Cheol Jeong, Sang Yeub Lee, Sung Yong Lee, Je Hyeong Kim, Chol Shin, Jae Jeong Shim, Kwang Ho In, Kyung Ho Kang, Se Hwa Yoo

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: A recently conducted randomized, phase III study that compared irinotecan plus cisplatin (IP) with etoposide plus cisplatin for the patients with extensive disease SCLC revealed a superior median survival rate and a superior 2-year survival rate for the IP combination therapy. Yet there have been few such reports on the patients suffering with limited disease SCLC (LD-SCLC). We conducted a phase II trial to evaluate the efficacy and toxicity of administering IP with concurrent radiotherapy for the patients with LD-SCLC. Patients and Methods: Twenty chemotherapy-naïve patients with LD-SCLC were enrolled in our study. The patients were treated with 40 mg/m2 irinotecan on days 1, 8 and 15 and with 60 mg/m2 cisplatin on day 1 every 4 weeks until a maximum of six cycles was delivered. Once-daily radiotherapy included the administration of 50.4 Gy in 28 fractions. After completion of the radiation therapy, the dose of irinotecan was increased to 60 mg/m2. Results: The response rate was 85% (CR: 6; partial response, PR: 11). The median survival was 20.0 months (95% CI: 15.6-24.4 months) with 1-year and 2-year overall survival rates of 85 and 35%, respectively. The median progression free survival (PFS) was 12 months (95% CI: 6.2-18.1 months) with a 1-year PFS of 36%. The major hematologic toxicities of this regimen were neutropenia (60%), leukopenia (55%), anemia (20%) and thrombocytopenia (10%). The non-hematologic toxicities were nausea/vomiting (55%), diarrhea (35%) and dysphagia (15%). Conclusions: Our data show that IP with concurrent radiotherapy is an effective and tolerable regimen for the treatment of LD-SCLC and these findings warrant further investigation.

Original languageEnglish
Pages (from-to)361-366
Number of pages6
JournalLung Cancer
Volume53
Issue number3
DOIs
Publication statusPublished - 2006 Sep 1

Fingerprint

irinotecan
Small Cell Lung Carcinoma
Cisplatin
Radiotherapy
Survival Rate
Disease-Free Survival
Leukopenia
Etoposide
Deglutition Disorders
Neutropenia
Thrombocytopenia
Nausea
Vomiting
Anemia
Diarrhea

Keywords

  • Cisplatin
  • Concurrent chemoradiation therapy
  • Irinotecan
  • Limited stage
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

@article{dbc144fdb7554b03acbeef3bc889d9fd,
title = "Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer",
abstract = "Background: A recently conducted randomized, phase III study that compared irinotecan plus cisplatin (IP) with etoposide plus cisplatin for the patients with extensive disease SCLC revealed a superior median survival rate and a superior 2-year survival rate for the IP combination therapy. Yet there have been few such reports on the patients suffering with limited disease SCLC (LD-SCLC). We conducted a phase II trial to evaluate the efficacy and toxicity of administering IP with concurrent radiotherapy for the patients with LD-SCLC. Patients and Methods: Twenty chemotherapy-na{\"i}ve patients with LD-SCLC were enrolled in our study. The patients were treated with 40 mg/m2 irinotecan on days 1, 8 and 15 and with 60 mg/m2 cisplatin on day 1 every 4 weeks until a maximum of six cycles was delivered. Once-daily radiotherapy included the administration of 50.4 Gy in 28 fractions. After completion of the radiation therapy, the dose of irinotecan was increased to 60 mg/m2. Results: The response rate was 85{\%} (CR: 6; partial response, PR: 11). The median survival was 20.0 months (95{\%} CI: 15.6-24.4 months) with 1-year and 2-year overall survival rates of 85 and 35{\%}, respectively. The median progression free survival (PFS) was 12 months (95{\%} CI: 6.2-18.1 months) with a 1-year PFS of 36{\%}. The major hematologic toxicities of this regimen were neutropenia (60{\%}), leukopenia (55{\%}), anemia (20{\%}) and thrombocytopenia (10{\%}). The non-hematologic toxicities were nausea/vomiting (55{\%}), diarrhea (35{\%}) and dysphagia (15{\%}). Conclusions: Our data show that IP with concurrent radiotherapy is an effective and tolerable regimen for the treatment of LD-SCLC and these findings warrant further investigation.",
keywords = "Cisplatin, Concurrent chemoradiation therapy, Irinotecan, Limited stage, Small-cell lung cancer",
author = "Jeong, {Hye Cheol} and Lee, {Sang Yeub} and Lee, {Sung Yong} and Kim, {Je Hyeong} and Chol Shin and Shim, {Jae Jeong} and In, {Kwang Ho} and Kang, {Kyung Ho} and Yoo, {Se Hwa}",
year = "2006",
month = "9",
day = "1",
doi = "10.1002/sim.2218",
language = "English",
volume = "53",
pages = "361--366",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer

AU - Jeong, Hye Cheol

AU - Lee, Sang Yeub

AU - Lee, Sung Yong

AU - Kim, Je Hyeong

AU - Shin, Chol

AU - Shim, Jae Jeong

AU - In, Kwang Ho

AU - Kang, Kyung Ho

AU - Yoo, Se Hwa

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Background: A recently conducted randomized, phase III study that compared irinotecan plus cisplatin (IP) with etoposide plus cisplatin for the patients with extensive disease SCLC revealed a superior median survival rate and a superior 2-year survival rate for the IP combination therapy. Yet there have been few such reports on the patients suffering with limited disease SCLC (LD-SCLC). We conducted a phase II trial to evaluate the efficacy and toxicity of administering IP with concurrent radiotherapy for the patients with LD-SCLC. Patients and Methods: Twenty chemotherapy-naïve patients with LD-SCLC were enrolled in our study. The patients were treated with 40 mg/m2 irinotecan on days 1, 8 and 15 and with 60 mg/m2 cisplatin on day 1 every 4 weeks until a maximum of six cycles was delivered. Once-daily radiotherapy included the administration of 50.4 Gy in 28 fractions. After completion of the radiation therapy, the dose of irinotecan was increased to 60 mg/m2. Results: The response rate was 85% (CR: 6; partial response, PR: 11). The median survival was 20.0 months (95% CI: 15.6-24.4 months) with 1-year and 2-year overall survival rates of 85 and 35%, respectively. The median progression free survival (PFS) was 12 months (95% CI: 6.2-18.1 months) with a 1-year PFS of 36%. The major hematologic toxicities of this regimen were neutropenia (60%), leukopenia (55%), anemia (20%) and thrombocytopenia (10%). The non-hematologic toxicities were nausea/vomiting (55%), diarrhea (35%) and dysphagia (15%). Conclusions: Our data show that IP with concurrent radiotherapy is an effective and tolerable regimen for the treatment of LD-SCLC and these findings warrant further investigation.

AB - Background: A recently conducted randomized, phase III study that compared irinotecan plus cisplatin (IP) with etoposide plus cisplatin for the patients with extensive disease SCLC revealed a superior median survival rate and a superior 2-year survival rate for the IP combination therapy. Yet there have been few such reports on the patients suffering with limited disease SCLC (LD-SCLC). We conducted a phase II trial to evaluate the efficacy and toxicity of administering IP with concurrent radiotherapy for the patients with LD-SCLC. Patients and Methods: Twenty chemotherapy-naïve patients with LD-SCLC were enrolled in our study. The patients were treated with 40 mg/m2 irinotecan on days 1, 8 and 15 and with 60 mg/m2 cisplatin on day 1 every 4 weeks until a maximum of six cycles was delivered. Once-daily radiotherapy included the administration of 50.4 Gy in 28 fractions. After completion of the radiation therapy, the dose of irinotecan was increased to 60 mg/m2. Results: The response rate was 85% (CR: 6; partial response, PR: 11). The median survival was 20.0 months (95% CI: 15.6-24.4 months) with 1-year and 2-year overall survival rates of 85 and 35%, respectively. The median progression free survival (PFS) was 12 months (95% CI: 6.2-18.1 months) with a 1-year PFS of 36%. The major hematologic toxicities of this regimen were neutropenia (60%), leukopenia (55%), anemia (20%) and thrombocytopenia (10%). The non-hematologic toxicities were nausea/vomiting (55%), diarrhea (35%) and dysphagia (15%). Conclusions: Our data show that IP with concurrent radiotherapy is an effective and tolerable regimen for the treatment of LD-SCLC and these findings warrant further investigation.

KW - Cisplatin

KW - Concurrent chemoradiation therapy

KW - Irinotecan

KW - Limited stage

KW - Small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=33747069666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747069666&partnerID=8YFLogxK

U2 - 10.1002/sim.2218

DO - 10.1002/sim.2218

M3 - Article

C2 - 16846662

AN - SCOPUS:33747069666

VL - 53

SP - 361

EP - 366

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -